Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback